{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/parkinsons-disease-multiple-ascending-dose#webpage",
"url": "https://www.fortrea.com/insights/parkinsons-disease-multiple-ascending-dose",
"name": "Parkinson’s disease: multiple ascending dose",
"description": "This Fortrea case study explores how Parkinson’s disease clinical trials were managed through pharmacokinetic studies conducted within a multiple ascending dose study during early-phase clinical development. The study evaluated pharmacokinetic and pharmacodynamic responses in patients with mild to moderate Parkinson’s disease while supporting dose escalation decisions across multiple dosing cohorts. The case study highlights operational requirements related to patient eligibility screening, inpatient coordination, pharmacology data collection, and continuous safety monitoring during early-phase clinical trials. Fortrea supported CNS clinical trial management through patient recruitment, operational oversight, and coordination of clinical pharmacology studies required to maintain progression throughout the study. By integrating structured execution with pharmacodynamic studies in clinical trial operations and dose escalation clinical trials, the approach supported efficient study management and reliable data collection within Parkinson’s disease research programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Parkinson’s disease: multiple ascending dose",
"item": "https://www.fortrea.com/insights/parkinsons-disease-multiple-ascending-dose"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/parkinsons-disease-multiple-ascending-dose#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/parkinsons-disease-multiple-ascending-dose#webpage"
},
"headline": "Parkinson’s Disease Dose Escalation and Pharmacokinetic Studies | Fortrea Case Study",
"description": "This Fortrea case study explores how Parkinson’s disease clinical trials were managed through pharmacokinetic studies conducted within a multiple ascending dose study during early-phase clinical development. The study evaluated pharmacokinetic and pharmacodynamic responses in patients with mild to moderate Parkinson’s disease while supporting dose escalation decisions across multiple dosing cohorts. The case study highlights operational requirements related to patient eligibility screening, inpatient coordination, pharmacology data collection, and continuous safety monitoring during early-phase clinical trials. Fortrea supported CNS clinical trial management through patient recruitment, operational oversight, and coordination of clinical pharmacology studies required to maintain progression throughout the study. By integrating structured execution with pharmacodynamic studies in clinical trial operations and dose escalation clinical trials, the approach supported efficient study management and reliable data collection within Parkinson’s disease research programs.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2024-11/GettyImages-1094024662%20%281%29.webp"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-14",
"dateModified": "2024-10-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/CS_0035_Parkinson%20Multi%20Dose_0424_HiRes.pdf",
"encodingFormat": "application/pdf"
}
}
]
}